433 research outputs found
Sphinx measurements of the 2009 solar minimum x-ray emission
The SphinX X-ray spectrophotometer on the CORONAS-PHOTON spacecraft measured
soft X-ray emission in the 1-15 keV energy range during the deep solar minimum
of 2009 with a sensitivity much greater than GOES. Several intervals are
identified when the X-ray flux was exceptionally low, and the flux and solar
X-ray luminosity are estimated. Spectral fits to the emission at these times
give temperatures of 1.7-1.9 MK and emission measures between 4 x 10^47 cm^-3
and 1.1 x 10^48 cm^-3. Comparing SphinX emission with that from the Hinode
X-ray Telescope, we deduce that most of the emission is from general coronal
structures rather than confined features like bright points. For one of 27
intervals of exceptionally low activity identified in the SphinX data, the
Sun's X-ray luminosity in an energy range roughly extrapolated to that of ROSAT
(0.1-2.4 keV) was less than most nearby K and M dwarfs.Comment: Astrophysical Journal, in press. 14 pp, 3 figure
Estimating a Personalized Basal Insulin Dose from Short-Term Closed-Loop Data in Type 2 Diabetes
In type 2 diabetes (T2D) treatment, finding a safe and effective basal
insulin dose is a challenge. The dose-response is highly individual and to
ensure safety, people with T2D titrate by slowly increasing the daily insulin
dose to meet treatment targets. This titration can take months. To ease and
accelerate the process, we use short-term artificial pancreas (AP) treatment
tailored for initial titration and apply it as a diagnostic tool. Specifically,
we present a method to automatically estimate a personalized daily dose of
basal insulin from closed-loop data collected with an AP. Based on AP-data from
a stochastic simulation model, we employ the continuous-discrete extended
Kalman filter and a maximum likelihood approach to estimate parameters in a
simple dose-response model for 100 virtual people. With the identified model,
we compute a daily dose of basal insulin to meet treatment targets for each
individual. We test the personalized dose and evaluate the treatment outcomes
against clinical reference values. In the tested simulation setup, the proposed
method is feasible. However, more extensive tests will reveal whether it can be
deemed safe for clinical implementation.Comment: 6 pages, 4 figures, 1 table. Accepted for publication in Proceedings
of the 2022 61st IEEE Conference on Decision and Control (CDC
Relaxation Methods for Mixed-Integer Optimal Control of Partial Differential Equations
We consider integer-restricted optimal control of systems governed by
abstract semilinear evolution equations. This includes the problem of optimal
control design for certain distributed parameter systems endowed with multiple
actuators, where the task is to minimize costs associated with the dynamics of
the system by choosing, for each instant in time, one of the actuators together
with ordinary controls. We consider relaxation techniques that are already used
successfully for mixed-integer optimal control of ordinary differential
equations. Our analysis yields sufficient conditions such that the optimal
value and the optimal state of the relaxed problem can be approximated with
arbitrary precision by a control satisfying the integer restrictions. The
results are obtained by semigroup theory methods. The approach is constructive
and gives rise to a numerical method. We supplement the analysis with numerical
experiments
Recommended from our members
Conceptualising quality of life for older people with aphasia
Background: There is an increasing need in speech and language therapy for clinicians to provide intervention in the context of the broader life quality issues for people with aphasia. However, there is no descriptive research that is explicitly focused on quality of life (QoL) from the perspectives of older people with aphasia.
Aims: The current study explores how older people with chronic aphasia who are living in the community describe their QoL in terms of what contributes to and detracts from the quality in their current and future lives. The study is descriptive in nature, and the purpose is to conceptualize the factors that influence QoL.
Methods & Procedures: Thirty older participants (16 women, 14 men) with mild to moderate aphasic impairment took part. All participants had adequate communication skills to participate: demonstrating reliable yes/no response and moderate auditory comprehension ability. Participants were interviewed in their own homes using six brief unprompted open questions about QoL, in a structured interview. The first five questions were drawn from previous gerontological research (Farquhar, 1995), and a sixth question specifically targeting communication was added. Content analysis was used, identifying discrete units of data and then coding these into concepts and factors. Additional demographic information was collected, and participants’ mood on day of interviewing was assessed using the Geriatric Depression Scale (Sheikh & Yesavage, 1986).
Outcomes & Results: Activities, verbal communication, people, and body functioning were the core factors in QoL for these participants, and they described how these factors both contributed quality in life as well as detracted from life quality. Other factors that influenced QoL included stroke, mobility, positive personal outlook, in/dependence, home and health. Whilst the findings are limited by the lack of probing of participants’ responses, the study does present preliminary evidence for what is important in QoL to older people with aphasia.
Conclusions: Quality of life for older people with predominantly mild to moderate chronic aphasia who are living in the community is multifactorial in nature. Some factors lie within the remit of speech and language therapy, some lie beyond the professional role, but all are relevant for consideration in rehabilitation and community practice. Further qualitative research is implicated to better understand QoL with aphasia, using in-depth interviewing with a broader range of people with aphasia
T-cell and B-cell perturbations identify distinct differences in HIV-2 compared with HIV-1-induced immunodeficiency
Suppression of HBV by Tenofovir in HBV/HIV coinfected patients : a systematic review and meta-analysis
Background: Hepatitis B coinfection is common in HIV-positive individuals and as antiretroviral therapy has made death due to AIDS less common, hepatitis has become increasingly important. Several drugs are available to treat hepatitis B. The most potent and the one with the lowest risk of resistance appears to be tenofovir (TDF). However there are several questions that remain unanswered regarding the use of TDF, including the proportion of patients that achieves suppression of HBV viral load and over what time, whether suppression is durable and whether prior treatment with other HBV-active drugs such as lamivudine, compromises the efficacy of TDF due to possible selection of resistant HBV strains.
Methods: A systematic review and meta-analysis following PRISMA guidelines and using multilevel mixed effects logistic regression, stratified by prior and/or concomitant use of lamivudine and/or emtricitabine.
Results: Data was available from 23 studies including 550 HBV/HIV coinfected patients treated with TDF. Follow up was for up to seven years but to ensure sufficient power the data analyses were limited to three years. The overall proportion achieving suppression of HBV replication was 57.4%, 79.0% and 85.6% at one, two and three years, respectively. No effect of prior or concomitant 3TC/FTC was shown. Virological rebound on TDF treatment was rare.
Interpretation: TDF suppresses HBV to undetectable levels in the majority of HBV/HIV coinfected patients with the proportion fully suppressed continuing to increase during continuous treatment. Prior treatment with 3TC/FTC does not compromise efficacy of TDF treatment. The use of combination treatment with 3TC/FTC offers no significant benefit over TDF alone
Surveillance of vancomycin-resistant enterococci reveals shift in dominating clones and national spread of a vancomycin-variable <i>vanA Enterococcus faecium</i> ST1421-CT1134 clone, Denmark, 2015 to March 2019
- …